



Ref. No.: EIKO/BSE/2024-25/06

Date: 13th May 2024

To,
Corporate Services Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.

Scrip Code: 540204

Subject: Outcome of the Board Meeting

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), We would like to inform you that at the meeting of the Board of Directors of the Company held on Monday, 13th May 2024 which commenced at 4.30 p.m. and ended at 6.00 p.m. have inter-alia, approved and taken on record the following:

1. Audited Financial Results of the Company for the Quarter and year ended 31st March 2024 along with Auditor's Report duly signed by the Auditor of the Company. A Copy of the same is enclosed herewith as **Annexure I**.
2. Declaration from Chief Financial Officer regarding unmodified opinion in the audit Report issued by the Thanawala & Company, Statutory auditor of the Company on Financial results. A Copy of the same is enclosed herewith as **Annexure II**.
3. Appointment of M/s Shravan Gupta & Associates, Practicing Company Secretary, as Secretarial Auditor for financial year 2024-25. The details of Secretarial Auditor as required under Regulation 30 of the SEBI (LODR), Regulation, 2015 read with Circular No SEBI/HO/CFD/CFD-PoD-I/P/CIR/2023/123 dated 13 July 2023 are mentioned in annexure attached as **Annexure – III**.
4. Appointment of M/s NP Rajput & Co., Chartered accountant, as Internal Auditor for financial year 2024-25. The details of Internal Auditor as required under Regulation 30 of the SEBI (LODR), Regulation, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-I/P/CIR/2023/123 dated 13 July 2023 are mentioned in annexure attached as **Annexure – IV**.
5. Further, details of the Company for the financial year ended 31st March 2024, in reference to SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, forms part of aforesaid standalone financial results which are enclosed herewith as **Annexure - V**.

For Eiko Lifesciences Limited

Jaid Kojar
Chief Financial Officer



Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of
EIKO LIFESCIENCES LIMITED**

Report on the Audit of Financial Results

Opinion

We have audited the annual financial results of **EIKO LIFESCIENCES LIMITED** (hereinafter referred to as the 'Company') for the year ended March 31, 2024 and the Balance Sheet and the Statement of Cash Flows as at and for the year ended on that date, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial results:

- i. are presented in accordance with the requirements of Regulation 33 and Regulation 52 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net loss and other comprehensive income and other financial information of the Company for the year ended March 31, 2024 and the balance sheet and the statement of cash flows as at and for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India.' Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Results' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.



Management and Board of Directors' Responsibilities for the Financial Results

These financial results have been prepared based on the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Company and the balance sheet and the statement of cash flows in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the financial results by the Directors of the Company, as aforesaid.

In preparing the financial results, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- i. Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- ii. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- iii. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- iv. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- v. Evaluate the overall presentation, structure and content of the standalone financial results including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- vi. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


Other Matter

The statement includes the results for the quarter ended March 31, 2024, being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2024, and the published unaudited year-to-date figures up to the third quarter of the current financial year, which are subjected to a limited review by us, as required under the Listing Regulations.

For Thanawala & Company

Chartered Accountants

Firm Reg. No.: 110948W


CA Vijay Thanawala

Proprietor

Membership No.: 015632



Place: Thane

Date: 13th May 2024

UDIN: 24015632BKGWWG1491


**EIKO LIFESCIENCES LIMITED**

(CIN: L65993MH1977PLC258134)

STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED 31-03-2024

(₹ in Lakhs)

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Revenue from operations	839.79	661.09	659.44	2,792.93	1,832.14
2	Other income	10.63	1.44	20.81	17.61	85.48
3	Total revenue	850.42	662.53	680.25	2,810.54	1,917.62
4	Expenses					
	Cost of material consumed	840.28	618.43	593.31	2,720.48	1,366.49
	Changes in inventories of finished stock and work-in-progress	(65.28)	(24.08)	0.65	(179.07)	242.85
	Employee benefits expense	5.30	6.49	6.34	22.07	28.71
	Depreciation and amortization expense	18.06	16.09	15.95	66.25	63.28
	Finance Cost	2.24	2.50	3.46	14.21	15.03
	Other expenses	7.54	13.99	22.76	68.17	98.64
5	Total expenses	808.14	633.42	642.46	2,712.12	1,815.00
6	Profit/(Loss) from ordinary activities before tax	42.29	29.10	37.79	98.42	102.62
7	Tax expense:					
	(1) Current tax	9.82	-	4.83	9.82	4.84
	(2) Earlier year's Tax	0.03	-	-	0.03	-
	(4) Deferred tax	1.14	5.35	4.67	13.42	20.91
8	Profit/(Loss) from ordinary activities after tax	31.29	23.76	28.29	75.15	76.88
9	Other Comprehensive Income (OCI) Item that will not be reclassified to profit or loss					
	Gain/(Loss) on recognised on fair valuation of Financial Assets	-	-	-	-	3.21
	Income tax relating to these items	-	-	-	-	(0.81)
10	Total Other Comprehensive Income (OCI)	-	-	-	-	2.40
11	Profit/ (Loss) for the Period	31.29	23.76	28.29	75.15	79.28
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	1,287.28	997.95	831.63	1,287.28	831.63
	Earnings Per Share (EPS) (Not annualised)					
	(1) Basic	0.28	0.24	0.29	0.73	0.79
	(2) Diluted	0.28	0.24	0.29	0.73	0.79





Notes:

1. The figures for the corresponding previous quarter/ year have been regrouped/reclassified wherever necessary, to make them comparable. The figures for quarter ended March 31, 2024, are balancing figures between the audited figures of the full financial year and the limited reviewed year-to date figures upto the third quarter of the financial year.
2. These financial results have been compiled from the related interim financial information which has been prepared in accordance with the recognition and measurement principles of the Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. These financial results have been prepared pursuant to the requirements of Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and comply with the disclosure requirements contained therein. The financial results for the year ended March 31, 2024, have been audited by the statutory auditors of the Company.
3. The above Audited Financial Results for the fourth quarter ended 31-03-2024 have been reviewed and recommended by Audit Committee and has been approved by the Board of Directors at its Meeting held on 13th May 2024. The statutory auditors of the Company have issued audit reports with unmodified opinion on the above results.
4. The Company has a single business segment, namely "Speciality & Fine Chemicals" therefore in the context of Ind As 108, disclosure of segment information is not applicable.
5. The Right Issue Committee of the Board of Directors of the Company at its meeting held on Thursday, 14-12-2023, approved the making of First and Final Call of Rs. 31.50/- (Rupees Thirty-One and Fifty Paise Only) on 55,44,178 Partly Paid-up Equity Shares. The Company fixed Friday, 22-12-2023 as the Record Date for the purpose of determining the holders of Partly Paid-up Equity Shares to whom the call notice with the dispatched for payment of the call. The listing approval for fully paid-up shares which were converted by payment of first and final call was received on 02-02-2024. The Right Issue Committee of the Board of Directors of the Company at its meeting held on 08-02-2024, decided to give another opportunity to the shareholders holding Rights Equity Shares, who did not pay the First and Final Call money earlier. Accordingly, listing approval of fully paid-up shares converted pursuant to payment of reminder call was received on 28-03-2024. Pursuant to IND AS 33, basic and diluted earnings per share for the previous periods have been restated for the bonus element in respect of right issue made during the quarter and year ended 31-03-2024.
6. Other Expenses of year ended 31.03.2024 includes expenses incurred on account of issue of Equity Shares on rights basis amounting to ₹ 25.97 Lakhs and Nil for Previous year.

For Eiko LifeSciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
DIN: 00061346



Date: 13th May 2024
Place: Thane



EIKO LIFESCIENCES LIMITED

(CIN: L65993MH1977PLC258134)

BALANCE SHEET AS OF 31-03-2024

PARTICULARS	AS AT 31-03-2024	AS AT 31-03-2023
ASSETS		
Non-current assets		
Property, Plant and Equipment	1,356.51	1,388.11
Financial Assets		
Investments	401.77	5.35
Loans	422.70	668.44
Other Financial Assets	-	112.26
	2,180.99	2,174.16
Current assets		
Inventories	338.56	90.76
Financial Assets		
Trade Receivables	1,313.38	710.56
Cash and cash equivalents	1,334.60	61.24
Other Current Assets	106.34	67.56
	3,092.88	930.12
TOTAL ASSET	5,273.87	3,104.28
EQUITY AND LIABILITIES		
EQUITY		
Equity Share capital	1,287.28	831.63
Other Equity	3,780.54	2,110.60
	5,067.83	2,942.23
LIABILITIES		
Non-current liabilities		
Financial Liabilities		
Non-Current Borrowings	-	-
Deferred Tax Liabilities	55.60	42.18
	55.60	42.18
Current liabilities		
Financial Liabilities		
Trade payables	138.05	104.53
Other financial liabilities	-	5.36
Current Tax Liabilities	6.44	-
Provisions	1.50	4.55
Other current Liability	4.46	5.43
	150.44	119.87
TOTAL LIABILITIES	5,273.87	3,104.28

For Eiko LifeSciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
DIN: 00061346



Date: 13th May 2024

Place: Thane

For Thanawala & Company

Chartered Accountants

Firm Reg. No.: 110948W

CA Vijay Thanawala

CA Vijay Thanawala

Proprietor

Membership No.: 015632





EIKO LIFESCIENCES LIMITED
(CIN: L65993MH1977PLC258134)
CASH FLOW STATEMENT AS OF 31-03-2024


(₹ in Lakhs)

PARTICULARS	YEAR ENDED 31-03-2024	YEAR ENDED 31-03-2023
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net (loss) / profit before tax	98.42	102.62
Adjustments for		
Depreciation and Amortisation Expense	66.25	63.28
Profit on sale of Investments	-	(3.15)
Dividend Income	(0.03)	(0.00)
Finance Costs	14.21	15.03
Interest Income classified as investing cash flow	(18.15)	(72.71)
Operating profit before working capital changes	160.70	105.07
Working capital adjustments:		
Increase / (Decrease) in Trade and Other Payables	33.52	(30.31)
Increase / (Decrease) in Provisions	(3.05)	1.20
Increase / (Decrease) in Other current Liabilities	(0.98)	0.44
Increase / (Decrease) in Other Financial Liabilities	(5.36)	(2.09)
(Increase) / Decrease in Inventories	(247.81)	454.99
(Increase) / Decrease in Trade Receivables	(602.82)	(254.33)
(Increase) / Decrease in Other Current Assets	(38.78)	139.88
Cash generated from / (used in) operations	(704.56)	414.85
Direct taxes paid (Net of Refunds)	(3.41)	7.53
Net cash (used in) / from generated from operating activities	(707.97)	422.38
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale/(Purchase) of Investments	(396.42)	21.02
Sale/(Purchase) of Fixed Assets	(34.65)	(22.47)
Income from dividend	0.03	0.00
Proceeds from Deposits	358.00	16.21
Interest Income	18.15	72.71
Net cash (used in) / generated from investing activities	(54.90)	87.47
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of shares	2,050.45	-
Interest paid	(14.21)	(15.03)
Proceeds /(Repayment) from borrowings	-	(455.32)
Net cash (used in) / from financing activities	2,036.24	(470.35)
Net decrease in cash and cash equivalents (A+B+C)	1,273.36	39.51
Cash and cash equivalents at the beginning of the year	61.24	21.73
Cash and cash equivalents at the end of the year	1,334.60	61.24

For Eiko LifeSciences Limited

L.K. Kabra

Laxmikant Kabra
Chairman
DIN: 00061346



Date: 13th May 2024
Place: Thane

For Thanawala & Company

Chartered Accountants
Firm Reg. No.: 110948W



Vijay Thanawala
CA Vijay Thanawala
Proprietor
Membership No.: 015632



Annexure II

To,
Corporate Services Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
1st Floor, Dalal Street,
Fort, Mumbai - 400001.

Scrip Code: 540204

Subject: Declaration in respect of Unmodified Opinion on Audited Financial Results of the Company for the Financial Year ended 31st March 2024.

In compliance with Regulation 33(3)(d) of Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016 and SEBI Master Circular No. SEBI/HO/ CFD/PoD2/CIR/ P/2023/120 dated July 11, 2023, we hereby declare that, Statutory Auditors of our Company M/s. Thanawala & Co, Chartered Accountants, have issued an Audit Report with unmodified opinion on Audited Financial Results of the Company for the quarter and year ended 31st March 2024.

You are requested to kindly take the aforementioned on record and oblige.

For Eiko Lifesciences Limited

Jaid Kojar
Chief Financial Officer



ANNEXURE – III

Brief details of appointment of M/s Shravan Gupta & Associates as Secretarial Auditor of the Company

We further submit the following details as required under the Listing Regulations read with SEBI Circular No SEBI/HO/CFD/CFD-PoD-I/P/CIR/2023/123 dated 13 July 2023 are annexed to this letter.

Sr. No	Particular	Appointment of Secretarial Auditor for FY 2024-25
1.	Name of the Firm	M/s Shravan Gupta & Associates
2.	Reason for change viz. appointment, Resignation, removal, death or otherwise;	Appointment as Secretarial Auditor of the Company.
3.	Date of Appointment	13 th May, 2024
4.	Term of Appointment	For Financial Year 2024-25
5.	Qualification & brief profile (in case of appointment)	M/s. Shravan Gupta & Associates is a Practicing Company Secretaries firm. The firm provides various Advisory Services on Corporate Compliances, Securities Law, incorporation, merger etc.
6.	Disclosure of relationship between Directors (in case of appointment of Director)	None



ANNEXURE – IV

Brief details of appointment of M/s M/s NP Rajput & Co as Internal Auditor of the Company.

We further submit the following details as required under the Listing Regulations read with SEBI Circular No SEBI/HO/CFD/CFD-PoD-I/P/CIR/2023/123 dated 13 July 2023 are annexed to this letter.

Sr. No	Particular	Appointment of Internal Auditor for FY 2024-25
1.	Name of the Firm	M/s NP Rajput & Co
2.	Reason for change viz. appointment, Resignation, removal, death or otherwise;	Appointment as Internal Auditor of the Company
3.	Date of Appointment	13 th May, 2024
4.	Term of Appointment	For Financial Year 2024-25
5.	Qualification & brief profile (in case of appointment)	M/s NP Rajput & Co. is having wide experience in Income tax Compliances, GST compliances, Accounting, Internal Audit, GST audit as well as handling major audit assignments.
6.	Disclosure of relationship between Directors (in case of appointment of Director)	None



ANNEXURE – V

Details of the Company in reference to SEBI Circular No. SEBI/HO/DDHS/DDHSRACPODI/P /CIR/2023/172 dated 19th October 2023, for the financial year ended 31st March 2024

Sr No	Particulars	Details
1	Outstanding Qualified Borrowings at the start of the financial year (Rs. In Crores)	Nil
2	Outstanding Qualified Borrowings at the end of the financial year (Rs. In Crores)	Nil
3	Highest credit rating of the company	Nil
4	Incremental borrowing done during the year (qualified borrowing) (Rs. In Crores)	Nil
5	Borrowings by way of issuance of debt securities during the year (Rs. In Crores)	Nil

For Eiko Lifesciences Limited

Jaid Kojar
Chief Financial Officer